Due to the simultaneous activation of the RAS/MAPK and AKT/mTOR pathways in human HCC, this model could be suitable for testing the efficacy of MAPK and mTOR inhibitors on HCC development and progression. Here, MTOR is linked to hepatocellular carcinoma.